Hi @Reginald, I invite you to comment on explanation about shots strategy.
First let me see if I understand you correctly. Are you saying there is a reasonable chance that the SP will increase on the FDA AA news and shorts will lose money, and you don't wonder why the short% has increased?
Here is my explanation:
In modern day when the intra-day SP can be manipulated by bots to induce fluctuations, "shorts" (or more like BIG DTs, e.g., JPM) make money on fluctuations more than they make money on falling SP. They are making a good few $100k's on daily basis just out of intraday fluctuation and this is just only out of one stock. Now, if the SP doubles or triples on any news, sure they will lose 50%-70% of their "short"-investment, that is just 50-70% of the money they traded that day. BUT by then, or more generally, in between two such events, they will have made some few %s each day and if such two events are separated by say 2-3 months then they will have made a hell of a lot of money ...
... and then regardless of the SP, high or low, so longs as they can cause fluctuation they repeat ... which is easy for them to do with in a stock that is running hot, some help from their bots and, YES, the main ingredient, the UNeducated and INexperienced retailers.
There are two ways out of this: either (a) cut "shorts" (corporate DTs) out. Not all stocks are or can be shorted, or (b) have a solid and robust comparative investment field and a promising product (the latter being ticked). That will make sure a steady SP (or minimal fluctuation to attract PESTS such as JPM). We do not have a real comparative field as currently the competition is blocked by GG+SI till another space opens up, that is the REVASCOR space.
MSB Price at posting:
$1.70 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)